Abstract
Background: Assessing nuclear features is diagnostically challenging in the aspect of thyroid pathology. The aim of this study was to determine whether pathologists could distinguish BRAF-like and RAS-like nuclear features morphologically and identify morphological features to differentiate thyroid tumors with RAS-like mutations from encapsulated papillary thyroid carcinoma (PTC) with predominant follicular growth and BRAFV600E mutation. Methods: Representative whole slide images of 16 encapsulated thyroid tumors with predominant follicular growth were reviewed by 12 thyroid pathologists using a web browser-based image viewer. Total nuclear score was calculated from semi-quantitatively scored eight nuclear features. The molecular profile of RAS and BRAF genes was determined by Sanger sequencing. Results: Total nuclear score ranging 0 to 24 could differentiate BRAF-like tumors from RAS-like tumors with a cut-off value of score 14. The interobserver agreement was the highest for the assessment of nuclear pseudoinclusions (NPIs) but the lowest for nuclear elongation and sickle-shaped nuclei. NPIs were found in tumors with BRAFV600E mutation, but not in tumors with RAS-like mutations. Total nuclear scores were significantly higher for tumors with BRAFV600E than for those with RAS-like mutations (P<0.001). Conclusion: Our results suggest that NPIs and high nuclear scores have diagnostic utility as rule-in markers for differentiating PTC with BRAFV600E mutation from benign or borderline follicular tumors with RAS-like mutations. Relaxation of rigid criteria for nuclear features resulted in an overdiagnosis of PTC. Immunostaining or molecular testing for BRAFV600E mutation is a useful adjunct for cases with high nuclear scores to identify true PTC.
Original language | English |
---|---|
Pages (from-to) | 123-133 |
Number of pages | 11 |
Journal | Endocrinology and Metabolism |
Volume | 36 |
Issue number | 1 |
DOIs | |
State | Published - Feb 2021 |
Bibliographical note
Funding Information:We would like to thank Dr. Deepali Jain (All India Institute of Medical Sciences, New Delhi, India) for providing her expert opinion. This research was supported by a grant (NRF-2020-R1F1A1070028) from the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Science and ICT.
Publisher Copyright:
Copyright © 2021 Korean Endocrine Society
Keywords
- Genes
- Medical overuse
- Mutation
- Observer variation
- Papillary
- Pathologists
- Proto-oncogene proteins B-raf
- Ras
- Thyroid cancer
- Thyroid neoplasms